You are here
GMSI Award 2015 – Updates on the GMSI 2013 and 2014 Award Winners
This lecture was given at the GMSI Award Event, 8th October 2015. The GMSI award was supported by Merck KGaA, Darmstadt, Germany
Professor Bates is in the Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Professor Bates briefly summarised progress made by the recipients of the 2013 and 2014 grants.
Dr. Joshua Bacon from New York (2013) used the sound lateralisation test to demonstrate slowed processing speed in multiple sclerosis patients with minimal to mild disability.
Dr. Kevin O'Connor from Yale (2013) has demonstrated that B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.
Dr. Daniel Harrison of Johns Hopkins University (2013) is studying the automated quantification of subpial demyelination and axonal injury with 7 Tesla MRI.
Dr. Thomas Thum of Hannover (2013) is working on an innovative microRNA-based kit for the detection and prognostic evaluation of patients with MS.
Dr. Stankoff from Paris (2014) is looking at PET scanning with [18F]flumenazil .
Drs Domercq and Matute from Bilbao, Spain, (2014) are working on re-educating microglia by P2X4 receptor manipulation as an alternative therapy in MS.
There is an inflammatory humoral response during CNS inflammation by infiltrating neutrophils. Dr. Axtell from Oklahoma (2014) has shown that this occurs through a BAFF- and APRIL-mediated mechanism.
Dr. Sue Metcalfe from Cambridge (2014) has continued her work on leukaemia inhibitory factor (LIF) nanotherapy to promote self-tolerance and myelin repair in MS.
Dr. Dominguez-Villar from Yale (2014) has identified several potential targets which when modulated may restore the suppressive capacity of regulatory T cells.
Professor Bates then summarised the selection procedure. In the initial presentation, the ideas are briefly presented and sent to the assessing panel in an anonymous form. The proposed research must be innovative, related to MS, robust and with a scientific rationale that withstands scrutiny. Moreover, it must be feasible within the time constraints and be of practical utility.
There were 146 initial applications in 2015. The review committee was chaired by David Bates, with 4 external and 3 internal experts. 8 proposals were invited and 4 grants awarded.
David Bates11/09/2015 - 10:41Professor Bates said that the GMSI [Grant for Multiple Sclerosis Innovation] was first awarded in 2013. Merck Serono provides research grants of up to 1 million Euros and thereby demonstrated its commitment to immunology...
Steven Hildemann11/09/2015 - 10:49Merck-Serono's pipeline focuses on difficult to treat diseases with a high unmet medical need, in the four areas of oncology, immuno-oncology, immunology and multiple sclerosis.
David Bates11/09/2015 - 11:00Professor Bates briefly summarised progress made by the recipients of the 2013 and 2014 grants.
Elga de Vries11/17/2015 - 13:31Microglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective.
Laura Airas11/17/2015 - 13:40In her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
GMSI Award 2015 – Driving microglia metabolism towards remyelination and restoration of brain damage in multiple sclerosis
Claudia Verderio11/17/2015 - 13:53According to Dr. Verderio, the new proposal stemmed from data on the biological activity of vesicles from microglia cells, on the proliferation, differentiation and myelination of oligodendrocyte precursor cells (OPCs).
Gabriele de Luca11/17/2015 - 14:03Dr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.